Barclays PLC Lexicon Pharmaceuticals, Inc. Transaction History
Barclays PLC
- $357 Billion
- Q4 2024
A detailed history of Barclays PLC transactions in Lexicon Pharmaceuticals, Inc. stock. As of the latest transaction made, Barclays PLC holds 243,316 shares of LXRX stock, worth $82,727. This represents 0.0% of its overall portfolio holdings.
Number of Shares
243,316
Previous 193,873
25.5%
Holding current value
$82,727
Previous $304,000
40.79%
% of portfolio
0.0%
Previous 0.0%
Shares
30 transactions
Others Institutions Holding LXRX
# of Institutions
133Shares Held
245MCall Options Held
52KPut Options Held
178K-
Artal Group S.A. Luxembourg, N4136MShares$46.3 Million100.0% of portfolio
-
Siren, L.L.C. New York, NY38.9MShares$13.2 Million1.27% of portfolio
-
Black Rock Inc. New York, NY9.89MShares$3.36 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.88MShares$3.36 Million0.0% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct8.99MShares$3.06 Million0.02% of portfolio
About LEXICON PHARMACEUTICALS, INC.
- Ticker LXRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 188,726,000
- Market Cap $64.2M
- Description
- Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; ...